Shionogi's RSV antiviral shows promise in hVIVO trial
LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...
FierceBiotech9d
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
Yahoo Finance8d
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.
London South East3d
Shionogi reports positive RSV trial results
The trial demonstrated a significant reduction in viral load for Shionogi's investigational oral RSV antiviral candidate, S-337395. S-337395, which has received Fast Track designation from the U.S ...
ENDPOINTS NEWS8d
Iron­wood's lay­offs; Sh­iono­gi’s RSV pill suc­ceeds in Phase 2
Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.
Shionogi targets JPY550B revenue through QOL focus and global expansion
Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...
London South East2d
hVIVO reports positive results from Shionogi RSV trial
(Sharecast News) - hVIVO reported positive results from a phase 2a respiratory syncytial virus (RSV) human challenge trial conducted on behalf of Shionogi on Wednesday. The AIM-traded firm said ...